Seres Therapeutics, Inc.
MCRB · XNASCIK 1609809fmd_1N3RTF70SV8EPT2Q4WGTAEPB6BManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2026, 52 periods
Latest annual · FY2025
Millions- Total revenues
- 1
- Operating income
- (94)
- Net income
- 6
- Free cash flow
- 1
Latest quarter · Q3 FY2026
Millions- Total revenues
- 1
- Operating income
- (16)
- Net income
- (16)
- Free cash flow
- (10)
Daily close · MCRBIEX trades only
Nov 04, 2025 to Nov 11, 2026 · 250 sessions1.51 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- -52.0%
- Revenue, 5 yearsFY2020 to FY2025
- -52.7%
- Net income, 5 yearsFY2020 to FY2025
- n/m
Seres Therapeutics, Inc. (MCRB) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $789,000 | $0 | 10-K 2026-03-12 · proof | |
| Operating income | -$94 million | -$121.3 million | 10-K 2026-03-12 · proof | |
| Net income | $5.7 million | $136,000 | +4,088.2% | 10-K 2026-03-12 · proof |
| Cash from operating activities | $1.1 million | -$148.6 million | 10-K 2026-03-12 · proof | |
| Free cash flow | $865,000 | -$149 million | 10-K 2026-03-12 · proof | |
| Total assets | $138.2 million | $139.8 million | -1.2% | 10-K 2026-03-12 · proof |
| Total liabilities | $94 million | $126 million | -25.4% | 10-K 2026-03-12 · proof |
| Cash and cash equivalents | $45.8 million | $30.8 million | +48.6% | 10-K 2026-03-12 · proof |
- What was Seres Therapeutics, Inc. (MCRB)'s revenue in fiscal 2025?
- Seres Therapeutics, Inc. (MCRB) reported revenue of $789,000 for fiscal 2025 (the year ended Dec 31, 2025), against $0 the year before. Source: the 10-K filed with the SEC on Mar 12, 2026. SEC
- What was Seres Therapeutics, Inc. (MCRB)'s operating income in fiscal 2025?
- Seres Therapeutics, Inc. (MCRB) reported operating income of -$94 million for fiscal 2025 (the year ended Dec 31, 2025), against -$121.3 million the year before. Source: the 10-K filed with the SEC on Mar 12, 2026. SEC
- What was Seres Therapeutics, Inc. (MCRB)'s net income in fiscal 2025?
- Seres Therapeutics, Inc. (MCRB) reported net income of $5.7 million for fiscal 2025 (the year ended Dec 31, 2025), against $136,000 the year before (+4,088.2%). Source: the 10-K filed with the SEC on Mar 12, 2026. SEC
- What was Seres Therapeutics, Inc. (MCRB)'s cash from operating activities in fiscal 2025?
- Seres Therapeutics, Inc. (MCRB) reported cash from operating activities of $1.1 million for fiscal 2025 (the year ended Dec 31, 2025), against -$148.6 million the year before. Source: the 10-K filed with the SEC on Mar 12, 2026. SEC
- What was Seres Therapeutics, Inc. (MCRB)'s free cash flow in fiscal 2025?
- Seres Therapeutics, Inc. (MCRB) reported free cash flow of $865,000 for fiscal 2025 (the year ended Dec 31, 2025), against -$149 million the year before. Source: the 10-K filed with the SEC on Mar 12, 2026. SEC
- What are Seres Therapeutics, Inc. (MCRB)'s total assets?
- As of Dec 31, 2025, Seres Therapeutics, Inc. (MCRB) reported total assets of $138.2 million, against $139.8 million a year earlier (-1.2%). Source: the 10-K filed with the SEC on Mar 12, 2026. SEC
- What are Seres Therapeutics, Inc. (MCRB)'s total liabilities?
- As of Dec 31, 2025, Seres Therapeutics, Inc. (MCRB) reported total liabilities of $94 million, against $126 million a year earlier (-25.4%). Source: the 10-K filed with the SEC on Mar 12, 2026. SEC
- What are Seres Therapeutics, Inc. (MCRB)'s cash and cash equivalents?
- As of Dec 31, 2025, Seres Therapeutics, Inc. (MCRB) reported cash and cash equivalents of $45.8 million, against $30.8 million a year earlier (+48.6%). Source: the 10-K filed with the SEC on Mar 12, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:MCRB&period_type=annual&limit=5"Information only, not investment advice.